Graham Cooper is the Chief Financial Officer and Chief Operating Officer of Tavo Biotherapeutics. Prior to Tavo, Cooper was the CFO for Receptos, which he joined prior to its IPO. At Receptos, he played a key role in managing through a dramatic growth phase and raising capital, culminating in its $7.8 billion sale to Celgene. He has also served as CFO and COO of Assembly Biosciences, developing innovative antiviral therapies for HBV, as well as other private and public biotechnology companies. Prior to his operating roles, Cooper held positions of increasing responsibility at Deutsche Bank Securities, including Director, Health Care Investment Banking. He began his career at Deloitte & Touche and was previously a CPA. He currently serves on the board of Beam Therapeutics (BEAM) and as chairman of the board of Kezar Life Sciences (KZR). Mr. Cooper received a BA in Economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business.